# US 2004/0204380 A1 · Antisense modulation of novel anti-apoptotic bcl-2-related proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0204380 A1
- Document ID: US20040204380A1
- Status: Published application
- Kind: A1
- Application number: 10/844,470
- Filed: 2004-05-12
- Published: 2004-10-14
- Earliest claimed: 1999-01-07
- Inventors: Elizabeth J. Ackermann; C. Frank Bennett; Nicholas M. Dean; Eric G. Marcusson
- Web page: https://patentgrep.com/patent/US20040204380A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/315: Phosphorothioates
- C12N 2310/318: where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N 2310/3181: Peptide nucleic acid, PNA
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/3341: 5-Methylcytosine
- C12N 2310/341: Gapmers, i.e. of the type ===---===
- C12N 2310/345: having at least two different backbone modifications
- C12N 2310/346: having a combination of backbone and sugar modifications
- Y02P 20/582: Recycling of unreacted starting or intermediate materials
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

Compositions and methods are provided for modulating the expression of novel anti-apoptotic bcl-2-related proteins. Antisense oligonucleotides targeted to nucleic acids encoding the human novel anti-apoptotic bcl-2-related proteins A1 and mcl-1 are preferred. Methods of using these compounds for modulation of novel anti-apoptotic bcl-2-related protein expression and for treatment of diseases associated with expression of novel anti-apoptotic bcl-2-related proteins are also provided. Also provided are methods of using these compounds for promoting apoptosis and for treatment of diseases for which promotion of apoptosis is desired.

## Claims

### Claim at position 1

1-41 (canceled).

### Claim at position 2

42: A method of inhibiting the expression of human mcl-1 (SEQ ID NO: 18) in cells or tissues comprising contacting said cells or tissues with an antisense compound 8 to 50 nucleobases in length which is targeted to a nucleic acid molecule encoding human mcl-1 so that expression of human mcl-1 is inhibited.

### Claim at position 3 (depends on 42)

43: The method of claim 42 wherein the antisense compound comprises at least one modified internucleoside linkage.

### Claim at position 4 (depends on 43)

44: The method of claim 43 wherein the modified internucleoside linkage is a phosphorothioate linkage.

### Claim at position 5 (depends on 42)

45: The method of claim 42 wherein the antisense compound comprises at least one modified sugar moiety.

### Claim at position 6 (depends on 45)

46: The method of claim 45 wherein the modified sugar moiety is a 2′-o-methoxyethyl sugar moiety.

### Claim at position 7 (depends on 42)

47: The method of claim 42 wherein the antisense compound comprises at least one modified nucleobase.

### Claim at position 8 (depends on 47)

48: The method of claim 47 wherein the modified nucleobase is a 2′-o-methoxyethyl modified cytosine or a 5′-methylcytosine.

### Claim at position 9 (depends on 48)

49: The method of claim 48 wherein the antisense compound is a chimeric oligonucleotide.

### Claim at position 10

50: A method of promoting apoptosis in human cells or tissues comprising contacting said cells or tissues with an antisense compound 8 to 50 nucleobases in length which is targeted to a nucleic acid molecule encoding human mcl-1 (SEQ ID NO:18) so that apoptosis is promoted.

### Claim at position 11

51: A method of treating a human having a disease or condition associated with human mcl-1 (SEQ ID NO:18) comprising administering to said human a therapeutically or prophylactically effective amount of an antisense compound 8 to 50 nucleobases in length which is targeted to a nucleic acid molecule encoding human mcl-1 so that expression of human mcl-1 is inhibited.

### Claim at position 12 (depends on 51)

52: The method of claim 51 wherein the disease is cancer.

### Claim at position 13 (depends on 51)

53: The method of claim 51 wherein the antisense compound is given in conjunction with a chemotherapeutic agent for the treatment of cancer.

### Claim at position 14 (depends on 51)

53: The method of claim 51 wherein the antisense compound comprises SEQ ID NO: 23.
